secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001447362-23-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M
--------------------------------------------------------------------------------

- Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.
- Total test reports 18,409 (+52% YoY); DecisionDx-Melanoma 8,559 (+16%), TissueCypher 2,829 (+310%).
- Net loss narrowed to $(6.9)M from $(20.2)M; adjusted EBITDA $6.6M vs $(9.6)M.
- Raised FY2023 revenue guidance to at least $200M from at least $180M.
- Operating cash flow positive $5.0M; cash $229.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/cstl-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001447362-23-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer